Argenx Bets $2.
2 Billion on a Vitiligo Breakthrough: What the Forte Biosciences Deal Means for Both Stocks The biopharma sector has been abuzz with consolidation deals in recent months, driven by factors like patent cliffs and policy changes.
These transactions highlight the industry's shifting priorities and challenges. Argenx SE's (NASDAQ:ARGX) acquisition of Forte Biosciences, Inc. (NASDAQ:FBRX) for $2.